Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival

PURPOSE: Sipuleucel-T is FDA approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) based on the IMPACT trial showing a 4.1-month benefit in median overall survival (OS) for patients receiving sipuleucel-T versus control. Although efficacy of sipuleucel-T is well estab...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Antonarakis, Emmanuel S., Small, Eric J., Petrylak, Daniel P., Quinn, David I., Kibel, Adam S., Chang, Nancy N., Dearstyne, Erica, Harmon, Matt, Campogan, Dwayne, Haynes, Heather, Vu, Tuyen, Sheikh, Nadeem A., Drake, Charles G.
Format: Artigo
Language:Inglês
Published: 2018
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6481607/
https://ncbi.nlm.nih.gov/pubmed/29858218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0638
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items